RxDoctor Payments Data

Melissa Bethany

Psychiatric/Mental Health · Roswell, NMNPI 1770943086

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $595, 4.2 times the $142 reported in 2021.

$1,498in general payments, 2019–2025

Across 87 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$266
  • Harmony Biosciences LLC$161
  • Alkermes, Inc.$159
  • Axsome Therapeutics, Inc.$156
  • Otsuka America Pharmaceutical, Inc.$151
  • Teva Pharmaceuticals USA, Inc.$136
  • plus $469 from 10 others

What the payments were for

  • Food & beverage$1,498100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,498 in reported general payments places this provider in the 80th percentile of 228 psychiatric/mental health providers in New Mexico.

See all psychiatric/mental health providers in New Mexico

Medicare billing

Part B allowed, 2024
$22,815
Medicare patients
55
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate42$73,186
VraylarCariprazine Hcl29$34,330
Aripiprazole39$3,160
Doxepin Hcl66$2,532
Olanzapine59$2,432
Ziprasidone Hcl28$1,949
Trazodone Hcl160$1,893
Bupropion XlBupropion Hcl81$1,805
Venlafaxine Hcl ErVenlafaxine Hcl99$1,731
Haloperidol39$1,484
Clonazepam72$1,479
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine41$1,332
Fluoxetine Hcl99$1,148
Divalproex Sodium ErDivalproex Sodium21$1,048
Alprazolam131$1,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$159$73,18642 claims
AbbVieVraylar$266$34,33029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 228 psychiatric/mental health providers in New Mexico.

Other psychiatric/mental health in Roswell

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →